Cached score snapshot

US.BDX · Becton Dickinson

110分制 38.8/110;5D動能v2 3/50;排序分 41.8/160 · Incomplete inputs

Ranking score 41.8/160
Main score 38.8/110
5D momentum v2 3/50
Rank #456
Setup grade F 19.4

Score breakdown

避免

Medium twelvedata

Score and price trend

F 19.4 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-16 07-21 08-21 09-24 10-22 $134.18$177.18$220.17 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.297 · anchors 120 +1.22% -0.72% / +5.01% 62.5% 3.8% Actual outcome pending · 0 / 3 bars observed
30D observation +8.30% +0.94% / +15.97% 81.3% 8.8% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 +1.09% -1.10% / +4.22% 60.6% 3.8% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-06-16 → 2026-10-22 · 90 archived points · 3 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 41.8
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 38.8/110 (避免)
5D momentum v2 3/50 (弱)
Score with momentum v2 41.8/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 185.713
ma50 171.4594
close 176.42
prevClose 179.8
avgVolume20 1638209
volumeRatio 1.03
changePercent -1.88

Metrics snapshot

close 176.42
volume 1679979
changePercent -1.88

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 38.8/110
Main rating 避免
5D momentum v2 3/50
Score with momentum v2 41.8/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.9/5 · 較差

Dimension score 2.9/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 296.3819
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0.4
marketCapPoints 0.5

資金流 — 6/20 · 較差

Dimension score 6/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 1.6
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.BDX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 4.6/15 · 較差

Dimension score 4.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 0.8

details

qqq

ma20 716.5275
ma50 710.6122
name QQQ
close 708.69
points 0.4

spy

ma20 767.5585
ma50 758.2458
name SPY
close 757.83
points 0.4
source twelvedata+fred
atrPct 2.326
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 7
catalystCount 0
catalystPoints 2

風險管理 — 7.4/10 · 良好

Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.326
turnoverUsdM 296.3819
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.BDX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 168.2128

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.7
take_profit_price 186.166
target_multiplier 1.9
technical_strength 1.88
take_profit_percent 5.5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.6521
diversificationPoints 2

技術信號 — 13.9/30 · 較差

Dimension score 13.9/30
Dimension grade 較差

Sub-items

bbPoints 1.8
adxPoints 3
sarPoints 1.2
vcpPoints 1
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1
vcp_reason 跌縮量(近10日3日);站上MA50;Ready=N;Confirm=N

vcp_metrics

up_days 4
vol_ref 1787640
down_days 5
vcp_ready false
above_ma50 true
avg_vol_10 1581300
avg_vol_20 1631785
avg_vol_30 1787640
range_pct_10 0.0862
range_pct_20 0.0936
range_pct_30 0.1736
up_expand_ok false
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.8846
dist_to_20d_high 0.0862
down_shrink_days 3
breakout_level_20d 193.07
vcp_breakout_confirm false
contraction_ratio_10_30 0.4967
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 0.8
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 1.2

情緒分析 — 2/10 · 較差

Dimension score 2/10
Dimension grade 較差

Sub-items

sentiment

score 2

details

source finnhub_news_keyword_model
articleCount 7
negativeHits 0
positiveHits 0
sentimentScoreRaw 0

sentimentData

raw {"id":142027197,"url":"https://finnhub.io/api/news?id=7fd23c787c97bfe50fed26561c991b2395d3536d42df1fb0c06d8a96ee37815e","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"BDX","summary":"Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...","category":"company","datetime":1788961637,"headline":"Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":141394944,"url":"https://finnhub.io/api/news?id=1f2d90bf76cdf9483bf09b320f85ea31b0881537420c526b48fe2815dd22eb5b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...","category":"company","datetime":1788405998,"headline":"Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium"}, {"id":141281776,"url":"https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...","category":"company","datetime":1787357437,"headline":"Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"}, {"id":141281777,"url":"https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...","category":"company","datetime":1787353919,"headline":"Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"}, {"id":141281771,"url":"https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...","category":"company","datetime":1787314239,"headline":"Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"}, {"id":141281778,"url":"https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.","category":"company","datetime":1787246580,"headline":"BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"}, {"id":141209513,"url":"https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.","category":"company","datetime":1786646640,"headline":"Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"}
raw_source {"id":142028634,"url":"https://finnhub.io/api/news?id=80e7de8999e6a41acd61752ba4a09ba315b534d097c582121d26f62ef8d54a24","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.","category":"company","datetime":1788977210,"headline":"BSX Stock: Is It Time To Buy Or Sell Puts?"}, {"id":142027197,"url":"https://finnhub.io/api/news?id=7fd23c787c97bfe50fed26561c991b2395d3536d42df1fb0c06d8a96ee37815e","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"BDX","summary":"Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...","category":"company","datetime":1788961637,"headline":"Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":142020706,"url":"https://finnhub.io/api/news?id=98087cf4336dff9b3f4e3b4d9f3663b0df0517898edbd958d7728bb9da1728ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.","category":"company","datetime":1788951690,"headline":"Becton Dickinson & Co's Dividend Analysis"}, {"id":141769004,"url":"https://finnhub.io/api/news?id=8a8af4f0e29e2e47735ebf112f4099a3ab5bb4698e572bde01e1576f55be9137","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.","category":"company","datetime":1788809880,"headline":"BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure"}, {"id":141485601,"url":"https://finnhub.io/api/news?id=a14fa2d71c991d1424c650e89ccc0365f647e29aec84a754bdf9a4133b2e0743","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates.","category":"company","datetime":1788562641,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week September 6"}, {"id":141455029,"url":"https://finnhub.io/api/news?id=9980113490b89d23a66c8ffb6cd96ecfaacbd42b6a644618293f4755fb4708bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.","category":"company","datetime":1788546339,"headline":"How Much Upside Can BSX Stock's Growth Deliver?"}, {"id":141464852,"url":"https://finnhub.io/api/news?id=50046c000a5f25411b9f89fce4ff5775ed5cfc999a09d0f0e5a698fa7805464f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.","category":"company","datetime":1788534513,"headline":"How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks?"}, {"id":141394944,"url":"https://finnhub.io/api/news?id=1f2d90bf76cdf9483bf09b320f85ea31b0881537420c526b48fe2815dd22eb5b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...","category":"company","datetime":1788405998,"headline":"Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium"}, {"id":141379530,"url":"https://finnhub.io/api/news?id=de9681a0ee09a77cf542eab958e12b5cad3038528e2ac5c18cac277bcda9770e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.","category":"company","datetime":1788375156,"headline":"The Wide Divide Priced Into Boston Scientific Stock"}, {"id":141360880,"url":"https://finnhub.io/api/news?id=9f26bd8922432f5a0314cbcbab75d980716eaa1f1418c04dae1e6c70cefd2ab9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.","category":"company","datetime":1788227277,"headline":"The Peer-Group Mispricing Sitting On BSX Stock"}, {"id":141360870,"url":"https://finnhub.io/api/news?id=3940eba2f9e552a33646a0657cfce9c2e5a582261d24899fe708d82efeab8c82","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.","category":"company","datetime":1788195506,"headline":"Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends"}, {"id":141363785,"url":"https://finnhub.io/api/news?id=52a212ee258f5c9d57aa79de1171a3e3e1c53086a47c9d6dea706f68d5ead932","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"The funding answers a documented gap. Hazardous drug classification remains fragmented across the NIOSH list, USP General Chapter <800>, ISOPP standards and European directives - frameworks that diverge in scope, definition and enforceability.","category":"company","datetime":1788194700,"headline":"Four Industry Sponsors Commit $100,000 to Launch the Medicinal Hazard Data Standardization Consortium"}, {"id":141360981,"url":"https://finnhub.io/api/news?id=7d5f22cbef8e157ea1ba869d201eb992d906f5ee88dcf71ac0c3a75b51a38721","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.","category":"company","datetime":1788191425,"headline":"Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”"}, {"id":141356087,"url":"https://finnhub.io/api/news?id=fdddf9d19eeb7556232b1d51c414a8c6fc8c2694dfd1ae7bff42c10e2cd63df0","image":"","source":"Benzinga","related":"BDX","summary":"B of A Securities analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.","category":"company","datetime":1788183564,"headline":"B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200"}, {"id":141336283,"url":"https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.","category":"company","datetime":1787894920,"headline":"Best Dividend Aristocrats For September 2026"}, {"id":141361650,"url":"https://finnhub.io/api/news?id=9d48bf108baf3cbf621771e0479bfd36e732a64ca11aeee9d74c79082830da73","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.","category":"company","datetime":1787851753,"headline":"Has BSX Stock Fallen Far Enough To Buy?"}, {"id":141362225,"url":"https://finnhub.io/api/news?id=bf2d640e767699ec5031bd72e404bb43a15159613842c3a3ce6cb260cf29de4e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the first planned interim analysis. This milestone places enr","category":"company","datetime":1787831400,"headline":"BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation"}, {"id":141363787,"url":"https://finnhub.io/api/news?id=0393fb4286881b8cdc9f393340080e70bdb7877bb6fd259aa7311c0ba2d1079f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time.","category":"company","datetime":1787778900,"headline":"BD to Present at Wells Fargo 21st Annual Healthcare Conference"}, {"id":141362447,"url":"https://finnhub.io/api/news?id=484896653bda1e33aa9eee763cb7174ea64c0aa188ed308c9504b6da583e96d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.","category":"company","datetime":1787777512,"headline":"Time To Squeeze 14% Yield Out Of Battered BSX Stock?"}, {"id":141322555,"url":"https://finnhub.io/api/news?id=fbc0fbca0d6d10fe9adb87c1b803cba253c534273106bbab742332765ee76728","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.","category":"company","datetime":1787677537,"headline":"The Floor Under BSX Stock Is Being Tested Again"}, {"id":141318019,"url":"https://finnhub.io/api/news?id=c5c25081435770e6bbefd0d753fa582441539bcf14cad848ec9e609bec944b8e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431876780/image_1431876780.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.","category":"company","datetime":1787674356,"headline":"Omnicell: Offers Good Value, But Uncertainty Remains"}, {"id":141314075,"url":"https://finnhub.io/api/news?id=cffee9de1f9c3c33dbc7f50b1cfc92908d0a7791b14fc63ba2cec5a04d3d6cb8","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285071364/image_1285071364.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.","category":"company","datetime":1787613074,"headline":"The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products"}, {"id":141363788,"url":"https://finnhub.io/api/news?id=035aa6b555e77e46f8b870a76caf03d55fa32ec6f77e1225d59f4fafc8e995b3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Waters' (WAT) Q4 guidance is conservative, as there is no inherent reason for legacy Waters' growth","category":"company","datetime":1787588044,"headline":"Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says"}, {"id":141322560,"url":"https://finnhub.io/api/news?id=8709dc095ddd161daa91d3a51dbfe911ac63dd53a225916c372e4403e7ec998d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.","category":"company","datetime":1787581560,"headline":"Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?"}, {"id":141307500,"url":"https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.","category":"company","datetime":1787547151,"headline":"Best Dividend Kings: August 2026"}, {"id":141281776,"url":"https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...","category":"company","datetime":1787357437,"headline":"Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"}, {"id":141281777,"url":"https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...","category":"company","datetime":1787353919,"headline":"Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"}, {"id":141281771,"url":"https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...","category":"company","datetime":1787314239,"headline":"Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"}, {"id":141281778,"url":"https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.","category":"company","datetime":1787246580,"headline":"BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"}, {"id":141278185,"url":"https://finnhub.io/api/news?id=b6f5547aae60787470f795a553206b912e475489277993b14623fbbb126e01ff","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.","category":"company","datetime":1787240880,"headline":"Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?"}, {"id":141265659,"url":"https://finnhub.io/api/news?id=72621766b3ba2eda3a73f80fafbf5c9b1ca88952ff8902906361281dbde1b406","image":"https://cdn.benzinga.com/files/images/story/2026/08/19/Becton-Dickinson.jpg?width=2048&height=1536","source":"Benzinga","related":"BDX","summary":"FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.","category":"company","datetime":1787146163,"headline":"What's Going On With Becton Dickinson Stock Wednesday?"}, {"id":141254663,"url":"https://finnhub.io/api/news?id=463574e3580ffb9f589901afe1e81274ac05739e4fc0c1300094be1add36c7be","image":"","source":"Benzinga","related":"BDX","summary":"https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson","category":"company","datetime":1787070386,"headline":"FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits"}, {"id":141251970,"url":"https://finnhub.io/api/news?id=4364ba6127479c07f5699a16fac7cbec7765cc2acfb197a9f0960759f80cbeac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.","category":"company","datetime":1786998600,"headline":"BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire"}, {"id":141251971,"url":"https://finnhub.io/api/news?id=5d59e7c1edd06ddbda2ed3402c661cfaba7913f97d47417d39994d445823ca9f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.","category":"company","datetime":1786981762,"headline":"Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?"}, {"id":141251978,"url":"https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.","category":"company","datetime":1786735380,"headline":"WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"}, {"id":141210844,"url":"https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.","category":"company","datetime":1786656117,"headline":"How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"}, {"id":141209513,"url":"https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.","category":"company","datetime":1786646640,"headline":"Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"}, {"id":141209552,"url":"https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.","category":"company","datetime":1786643280,"headline":"WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"}, {"id":141208353,"url":"https://finnhub.io/api/news?id=0244c9c694007d4e9937211ed2556b17a0a629e6bd558f9db42bfdcb99e0ca05","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227232848/image_2227232848.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"BDX","summary":"Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns—get the latest Wall St view.","category":"company","datetime":1786630407,"headline":"Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing"}, {"id":141210225,"url":"https://finnhub.io/api/news?id=423fe7ea2c1239076de65c5eca506f8cc8900f3c8c77dc2afb521ed30649aa14","image":"https://cdn.benzinga.com/files/images/story/2026/08/13/Stuttgart--Germany---03-07-2025-Smartpho.jpg?width=2048&height=1536","source":"Benzinga","related":"BDX","summary":"FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.","category":"company","datetime":1786629609,"headline":"Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products"}, {"id":141205682,"url":"https://finnhub.io/api/news?id=c145b4c41426e9b58210d33118893e1097cdb793d06d7fe21c7c073bb3e302c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.","category":"company","datetime":1786625700,"headline":"Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins"}, {"id":141212086,"url":"https://finnhub.io/api/news?id=46fc8b9320357e1303faa1963d2c6192491e6b8dbb4a6ce6ae8a011aefad67fa","image":"","source":"Benzinga","related":"BDX","summary":"RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.","category":"company","datetime":1786618414,"headline":"RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190"}, {"id":141202126,"url":"https://finnhub.io/api/news?id=554f4bd07663b1b9854e9df4a2804b7668b8c19b8a271fbc4748d6e95e018cb1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"BDX","summary":"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.","category":"company","datetime":1786531800,"headline":"BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial"}, {"id":141193463,"url":"https://finnhub.io/api/news?id=1bf62fb7bb5e82e56670edfaeb004a350ad4c7f11cd7cec590d3b4f465f7e66e","image":"","source":"Benzinga","related":"BDX","summary":"Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026","category":"company","datetime":1786517667,"headline":"Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias"}
data_source finnhub_news_keyword_model
article_count 7
negative_hits 0
positive_hits 0
recomputed_at_score true
sentiment_score_raw 0
source_article_count 44
discarded_article_count 37
sentimentPoints 2

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.9 5/110 58% 2.9
資金流 6 20/110 30% 6
市場環境 4.6 15/110 30.67% 4.6
催化劑 2 20/110 10% 2
風險管理 7.4 10/110 74% 7.4
技術信號 13.9 30/110 46.33% 13.9
情緒分析 2 10/110 20% 2

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 3/50
ret_5d -0.0592
max_score 50
max_total 50
raw_total 3
vcp_bonus 0
vol_ratio 1.0295
ret_points 0
vol_points 2
range_ratio 0.8622
volat_points 0
day_range_pct 0.0185
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.326
turnoverUsdM 296.3819
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.BDX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 168.2128

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 2
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.7
take_profit_price 186.166
target_multiplier 1.9
technical_strength 1.88
take_profit_percent 5.5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.6521
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.9/5分
資金流分析總分: 6/20分
市場環境分析總分: 4.6/15分
催化劑分析: 2/20分
風險管理總分: 7.4/10分
技術信號分析總分: 13.9/30分
情緒分析: 2/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 4.1036
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.33
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -170.21
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.088
kdj
d 25.77
j -5.35
k 15.4
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 43.71
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 28214921
recentSlope -292867.9
previousSlope 227460
rsi
value 28.46
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 186.4953
position SAR喺價上
distancePct 5.71
previousTrend 下降
ma50
value 171.4594
macd
macd 2.4135
trend 中性偏多
signal 4.7995
histogram -2.386
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 185.861
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.03
score 6
avgVolume 1638209
currentVolume 1679979
derived
ma20 185.713
ma50 171.4594
prevClose 179.8
avgVolume10 1608988
avgVolume20 1638209
changePercent -1.88
avgVolumeForScore 1638209
ma_cross
ma20 185.713
ma50 171.4594
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 186.071
prevMa50 170.9576
spreadPct 8.31
isVolumeBreakout false
bollinger
lower 177.1498
upper 194.2762
position 下半部
rsi_short
value 9.16
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.03

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.3260401315043646,
        "turnoverUsdM": 296.38189518,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BDX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 168.2128,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.7,
      "take_profit_price": 186.166,
      "target_multiplier": 1.9,
      "technical_strength": 1.88,
      "take_profit_percent": 5.5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.652080263008729,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 41.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 38.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 185.713,
    "ma50": 171.4594,
    "close": 176.42,
    "prevClose": 179.8,
    "avgVolume20": 1638209,
    "volumeRatio": 1.03,
    "changePercent": -1.88
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.05919368600682606,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 1.0295345281394301,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 0.862191523458612,
      "volat_points": 0,
      "day_range_pct": 0.018535313456524264,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 41.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 58,
        "contribution": 2.9
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 13.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 46.33,
        "contribution": 13.9
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 38.8,
    "details": [
      "基本面分析總分: 2.9/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 13.9/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.9,
      "資金流": 6,
      "市場環境": 4.6,
      "情緒分析": 2,
      "技術信號": 13.9,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 296.38189518,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BDX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.3260401315043646,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142027197,
                "url": "https://finnhub.io/api/news?id=7fd23c787c97bfe50fed26561c991b2395d3536d42df1fb0c06d8a96ee37815e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...",
                "category": "company",
                "datetime": 1788961637,
                "headline": "Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141394944,
                "url": "https://finnhub.io/api/news?id=1f2d90bf76cdf9483bf09b320f85ea31b0881537420c526b48fe2815dd22eb5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...",
                "category": "company",
                "datetime": 1788405998,
                "headline": "Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium"
              },
              {
                "id": 141281776,
                "url": "https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...",
                "category": "company",
                "datetime": 1787357437,
                "headline": "Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"
              },
              {
                "id": 141281777,
                "url": "https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...",
                "category": "company",
                "datetime": 1787353919,
                "headline": "Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"
              },
              {
                "id": 141281771,
                "url": "https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...",
                "category": "company",
                "datetime": 1787314239,
                "headline": "Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141209513,
                "url": "https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.",
                "category": "company",
                "datetime": 1786646640,
                "headline": "Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"
              }
            ],
            "raw_source": [
              {
                "id": 142028634,
                "url": "https://finnhub.io/api/news?id=80e7de8999e6a41acd61752ba4a09ba315b534d097c582121d26f62ef8d54a24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak.  Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point.  Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.",
                "category": "company",
                "datetime": 1788977210,
                "headline": "BSX Stock: Is It Time To Buy Or Sell Puts?"
              },
              {
                "id": 142027197,
                "url": "https://finnhub.io/api/news?id=7fd23c787c97bfe50fed26561c991b2395d3536d42df1fb0c06d8a96ee37815e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...",
                "category": "company",
                "datetime": 1788961637,
                "headline": "Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142020706,
                "url": "https://finnhub.io/api/news?id=98087cf4336dff9b3f4e3b4d9f3663b0df0517898edbd958d7728bb9da1728ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09.  This cash dividend is payable on 2026-09-30.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.",
                "category": "company",
                "datetime": 1788951690,
                "headline": "Becton Dickinson & Co's Dividend Analysis"
              },
              {
                "id": 141769004,
                "url": "https://finnhub.io/api/news?id=8a8af4f0e29e2e47735ebf112f4099a3ab5bb4698e572bde01e1576f55be9137",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.",
                "category": "company",
                "datetime": 1788809880,
                "headline": "BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure"
              },
              {
                "id": 141485601,
                "url": "https://finnhub.io/api/news?id=a14fa2d71c991d1424c650e89ccc0365f647e29aec84a754bdf9a4133b2e0743",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1788562641,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 6"
              },
              {
                "id": 141455029,
                "url": "https://finnhub.io/api/news?id=9980113490b89d23a66c8ffb6cd96ecfaacbd42b6a644618293f4755fb4708bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.",
                "category": "company",
                "datetime": 1788546339,
                "headline": "How Much Upside Can BSX Stock's Growth Deliver?"
              },
              {
                "id": 141464852,
                "url": "https://finnhub.io/api/news?id=50046c000a5f25411b9f89fce4ff5775ed5cfc999a09d0f0e5a698fa7805464f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1788534513,
                "headline": "How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks?"
              },
              {
                "id": 141394944,
                "url": "https://finnhub.io/api/news?id=1f2d90bf76cdf9483bf09b320f85ea31b0881537420c526b48fe2815dd22eb5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...",
                "category": "company",
                "datetime": 1788405998,
                "headline": "Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium"
              },
              {
                "id": 141379530,
                "url": "https://finnhub.io/api/news?id=de9681a0ee09a77cf542eab958e12b5cad3038528e2ac5c18cac277bcda9770e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.",
                "category": "company",
                "datetime": 1788375156,
                "headline": "The Wide Divide Priced Into Boston Scientific Stock"
              },
              {
                "id": 141360880,
                "url": "https://finnhub.io/api/news?id=9f26bd8922432f5a0314cbcbab75d980716eaa1f1418c04dae1e6c70cefd2ab9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.",
                "category": "company",
                "datetime": 1788227277,
                "headline": "The Peer-Group Mispricing Sitting On BSX Stock"
              },
              {
                "id": 141360870,
                "url": "https://finnhub.io/api/news?id=3940eba2f9e552a33646a0657cfce9c2e5a582261d24899fe708d82efeab8c82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.",
                "category": "company",
                "datetime": 1788195506,
                "headline": "Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends"
              },
              {
                "id": 141363785,
                "url": "https://finnhub.io/api/news?id=52a212ee258f5c9d57aa79de1171a3e3e1c53086a47c9d6dea706f68d5ead932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The funding answers a documented gap. Hazardous drug classification remains fragmented across the NIOSH list, USP General Chapter <800>, ISOPP standards and European directives - frameworks that diverge in scope, definition and enforceability.",
                "category": "company",
                "datetime": 1788194700,
                "headline": "Four Industry Sponsors Commit $100,000 to Launch the Medicinal Hazard Data Standardization Consortium"
              },
              {
                "id": 141360981,
                "url": "https://finnhub.io/api/news?id=7d5f22cbef8e157ea1ba869d201eb992d906f5ee88dcf71ac0c3a75b51a38721",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.",
                "category": "company",
                "datetime": 1788191425,
                "headline": "Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”"
              },
              {
                "id": 141356087,
                "url": "https://finnhub.io/api/news?id=fdddf9d19eeb7556232b1d51c414a8c6fc8c2694dfd1ae7bff42c10e2cd63df0",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "B of A Securities  analyst Travis Steed   maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.",
                "category": "company",
                "datetime": 1788183564,
                "headline": "B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141361650,
                "url": "https://finnhub.io/api/news?id=9d48bf108baf3cbf621771e0479bfd36e732a64ca11aeee9d74c79082830da73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.",
                "category": "company",
                "datetime": 1787851753,
                "headline": "Has BSX Stock Fallen Far Enough To Buy?"
              },
              {
                "id": 141362225,
                "url": "https://finnhub.io/api/news?id=bf2d640e767699ec5031bd72e404bb43a15159613842c3a3ce6cb260cf29de4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the first planned interim analysis. This milestone places enr",
                "category": "company",
                "datetime": 1787831400,
                "headline": "BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation"
              },
              {
                "id": 141363787,
                "url": "https://finnhub.io/api/news?id=0393fb4286881b8cdc9f393340080e70bdb7877bb6fd259aa7311c0ba2d1079f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time.",
                "category": "company",
                "datetime": 1787778900,
                "headline": "BD to Present at Wells Fargo 21st Annual Healthcare Conference"
              },
              {
                "id": 141362447,
                "url": "https://finnhub.io/api/news?id=484896653bda1e33aa9eee763cb7174ea64c0aa188ed308c9504b6da583e96d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.",
                "category": "company",
                "datetime": 1787777512,
                "headline": "Time To Squeeze 14% Yield Out Of Battered BSX Stock?"
              },
              {
                "id": 141322555,
                "url": "https://finnhub.io/api/news?id=fbc0fbca0d6d10fe9adb87c1b803cba253c534273106bbab742332765ee76728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.",
                "category": "company",
                "datetime": 1787677537,
                "headline": "The Floor Under BSX Stock Is Being Tested Again"
              },
              {
                "id": 141318019,
                "url": "https://finnhub.io/api/news?id=c5c25081435770e6bbefd0d753fa582441539bcf14cad848ec9e609bec944b8e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1431876780/image_1431876780.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.",
                "category": "company",
                "datetime": 1787674356,
                "headline": "Omnicell: Offers Good Value, But Uncertainty Remains"
              },
              {
                "id": 141314075,
                "url": "https://finnhub.io/api/news?id=cffee9de1f9c3c33dbc7f50b1cfc92908d0a7791b14fc63ba2cec5a04d3d6cb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285071364/image_1285071364.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.",
                "category": "company",
                "datetime": 1787613074,
                "headline": "The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products"
              },
              {
                "id": 141363788,
                "url": "https://finnhub.io/api/news?id=035aa6b555e77e46f8b870a76caf03d55fa32ec6f77e1225d59f4fafc8e995b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Waters' (WAT) Q4 guidance is conservative, as there is no inherent reason for legacy Waters' growth",
                "category": "company",
                "datetime": 1787588044,
                "headline": "Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says"
              },
              {
                "id": 141322560,
                "url": "https://finnhub.io/api/news?id=8709dc095ddd161daa91d3a51dbfe911ac63dd53a225916c372e4403e7ec998d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.",
                "category": "company",
                "datetime": 1787581560,
                "headline": "Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141281776,
                "url": "https://finnhub.io/api/news?id=2f1b17084b151b718d76db87b27393bf4e58e225aa9b459c14e656bb2f0102a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...",
                "category": "company",
                "datetime": 1787357437,
                "headline": "Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends"
              },
              {
                "id": 141281777,
                "url": "https://finnhub.io/api/news?id=5d979822df07bfb775e40ae865aa76e338396978b09632b2f3149d5750dcc8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...",
                "category": "company",
                "datetime": 1787353919,
                "headline": "Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks"
              },
              {
                "id": 141281771,
                "url": "https://finnhub.io/api/news?id=f2237a51bc1885d9db19f32f63990e7dfd01b872e2eb46e336cdb6805393d8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...",
                "category": "company",
                "datetime": 1787314239,
                "headline": "Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141278185,
                "url": "https://finnhub.io/api/news?id=b6f5547aae60787470f795a553206b912e475489277993b14623fbbb126e01ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.",
                "category": "company",
                "datetime": 1787240880,
                "headline": "Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?"
              },
              {
                "id": 141265659,
                "url": "https://finnhub.io/api/news?id=72621766b3ba2eda3a73f80fafbf5c9b1ca88952ff8902906361281dbde1b406",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Becton-Dickinson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.",
                "category": "company",
                "datetime": 1787146163,
                "headline": "What's Going On With Becton Dickinson Stock Wednesday?"
              },
              {
                "id": 141254663,
                "url": "https://finnhub.io/api/news?id=463574e3580ffb9f589901afe1e81274ac05739e4fc0c1300094be1add36c7be",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson",
                "category": "company",
                "datetime": 1787070386,
                "headline": "FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits"
              },
              {
                "id": 141251970,
                "url": "https://finnhub.io/api/news?id=4364ba6127479c07f5699a16fac7cbec7765cc2acfb197a9f0960759f80cbeac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.",
                "category": "company",
                "datetime": 1786998600,
                "headline": "BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire"
              },
              {
                "id": 141251971,
                "url": "https://finnhub.io/api/news?id=5d59e7c1edd06ddbda2ed3402c661cfaba7913f97d47417d39994d445823ca9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1786981762,
                "headline": "Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786735380,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141210844,
                "url": "https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.",
                "category": "company",
                "datetime": 1786656117,
                "headline": "How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"
              },
              {
                "id": 141209513,
                "url": "https://finnhub.io/api/news?id=318af3ce9d68f4d59c789d9468e33cee99853f72596451c8a34c2d7d1c3e5790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.",
                "category": "company",
                "datetime": 1786646640,
                "headline": "Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141208353,
                "url": "https://finnhub.io/api/news?id=0244c9c694007d4e9937211ed2556b17a0a629e6bd558f9db42bfdcb99e0ca05",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227232848/image_2227232848.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns—get the latest Wall St view.",
                "category": "company",
                "datetime": 1786630407,
                "headline": "Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing"
              },
              {
                "id": 141210225,
                "url": "https://finnhub.io/api/news?id=423fe7ea2c1239076de65c5eca506f8cc8900f3c8c77dc2afb521ed30649aa14",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Stuttgart--Germany---03-07-2025-Smartpho.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.",
                "category": "company",
                "datetime": 1786629609,
                "headline": "Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products"
              },
              {
                "id": 141205682,
                "url": "https://finnhub.io/api/news?id=c145b4c41426e9b58210d33118893e1097cdb793d06d7fe21c7c073bb3e302c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.",
                "category": "company",
                "datetime": 1786625700,
                "headline": "Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins"
              },
              {
                "id": 141212086,
                "url": "https://finnhub.io/api/news?id=46fc8b9320357e1303faa1963d2c6192491e6b8dbb4a6ce6ae8a011aefad67fa",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "RBC Capital  analyst Kendall Au   maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.",
                "category": "company",
                "datetime": 1786618414,
                "headline": "RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190"
              },
              {
                "id": 141202126,
                "url": "https://finnhub.io/api/news?id=554f4bd07663b1b9854e9df4a2804b7668b8c19b8a271fbc4748d6e95e018cb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.",
                "category": "company",
                "datetime": 1786531800,
                "headline": "BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial"
              },
              {
                "id": 141193463,
                "url": "https://finnhub.io/api/news?id=1bf62fb7bb5e82e56670edfaeb004a350ad4c7f11cd7cec590d3b4f465f7e66e",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026",
                "category": "company",
                "datetime": 1786517667,
                "headline": "Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 44,
            "discarded_article_count": 37
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.9,
        "grade": "較差",
        "items": {
          "bbPoints": 1.8,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日3日);站上MA50;Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1787640,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1581300,
              "avg_vol_20": 1631785,
              "avg_vol_30": 1787640,
              "range_pct_10": 0.08621465820201778,
              "range_pct_20": 0.0936402165287382,
              "range_pct_30": 0.17356312776329225,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8845740753171779,
              "dist_to_20d_high": 0.08623818509521272,
              "down_shrink_days": 3,
              "breakout_level_20d": 193.070007,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4967337205376853
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.3260401315043646,
              "turnoverUsdM": 296.38189518,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BDX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 168.2128,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.7,
            "take_profit_price": 186.166,
            "target_multiplier": 1.9,
            "technical_strength": 1.88,
            "take_profit_percent": 5.5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.652080263008729,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BDX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 4.1036,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.33
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -170.21
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.088
    },
    "kdj": {
      "d": 25.77,
      "j": -5.35,
      "k": 15.4,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 43.71
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 28214921,
      "recentSlope": -292867.9,
      "previousSlope": 227460
    },
    "rsi": 28.46,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 186.4953,
      "position": "SAR喺價上",
      "distancePct": 5.71,
      "previousTrend": "下降"
    },
    "ma50": 171.4594,
    "macd": {
      "macd": 2.413540923003467,
      "trend": "中性偏多",
      "signal": 4.799530494119576,
      "histogram": -2.3859895711161094
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 185.861,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.03,
      "score": 6,
      "avgVolume": 1638209,
      "currentVolume": 1679979
    },
    "derived": {
      "ma20": 185.713,
      "ma50": 171.4594,
      "prevClose": 179.8,
      "avgVolume10": 1608988,
      "avgVolume20": 1638209,
      "changePercent": -1.88,
      "avgVolumeForScore": 1638209
    },
    "ma_cross": {
      "ma20": 185.713,
      "ma50": 171.4594,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 186.071,
      "prevMa50": 170.9576,
      "spreadPct": 8.31,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 177.1498,
      "upper": 194.2762,
      "position": "下半部"
    },
    "rsi_short": 9.16,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.03
    }
  }
}

Raw metrics JSON

{
  "close": 176.42,
  "volume": 1679979,
  "changePercent": -1.88
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.